UK cancer services have slipped into a fragile state, a new Lancet Oncology study shows. The research, led by the International Agency for Research on Cancer, found that more than one in five diagnoses were missed during the pandemic, the worst performance among seven industrialised nations in 2020, the figure hit 22 per cent.

Across the seven countries, researchers estimated 56,000 fewer cancer diagnoses than expected in 2020, implying about 16 per cent of cases slipped through the cracks. The UK led the drop, with a 22 per cent shortfall, and lagged in recovering diagnostic rates even as other nations, like Denmark, rebounded quickly by the end of 2021.

Michelle Mitchell, chief executive of Cancer Research UK, warned that missed cases likely faced poorer outcomes. She urged an overhaul of planning and investment, stressing the need to expand diagnostic capacity, grow the workforce, and build resilience against future shocks. Without such changes, the NHS risks repeating the pandemic’s diagnostic collapse in the next decade.

Compared with Denmark and Norway, which kept services open and recovered faster, the UK’s lockdown messaging discouraged people from seeking care. The NHS claims urgent referrals rebounded by September, yet the study suggests early‑stage diagnosis rates remain lower than pre‑pandemic levels, underscoring the urgency for sustained investment to prevent future backlogs and protect outcomes globally.